NCT04191096 · Interventional trial
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Overall registry status Terminated
Phase 3
Conditions Metastatic Hormone-Sensitive Prostate Cancer
Delaware Valley sites
- MidLantic Urology ( Site 0273) · Bala-Cynwyd, PA · Montgomery County
First posted
Registry updated
Added to the directory